Clinical Trials Browser

Phase 1/2 × Withdrawn × decitabine and cedazuridine drug combination × Clear all

NCT06284460 2026-02-13

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Withdrawn

Classical hematologyMyeloid

Anemia, Refractory, with Excess of Blasts, Myeloproliferative Disorders

NCT06113289 2025-03-12

A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04013880 2020-07-07

ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1/2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute